Efficacy and Safety of Treating Refractory Bone and Soft Tissue Sarcoma with Anlotinib in Different Treatment Patterns.

Published in: Computational and mathematical methods in medicine (2022)

Anlotinib alone showed encouraging efficacy and favorable tolerability in refractory bone and soft tissue sarcoma. Anlotinib plus chemotherapy did not show a significant clinical benefit compared with anlotinib alone. Anlotinib showed better tumor control when used as first-line drug treatment in refractory bone and soft tissue sarcoma.

Keyphrases

bone mineral density
soft tissue
squamous cell carcinoma
randomized controlled trial
bone regeneration
radiation therapy
postmenopausal women
combination therapy
locally advanced
rectal cancer
study protocol
adverse drug